967 related articles for article (PubMed ID: 9007946)
1. p53 expression in uveal malignant melanomas.
Jay V; Yi Q; Hunter WS; Zielenska M
Pathology; 1996 Nov; 28(4):306-8. PubMed ID: 9007946
[TBL] [Abstract][Full Text] [Related]
2. p53 Immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid.
Chowers I; Folberg R; Livni N; Pe'er J
Curr Eye Res; 2002 Feb; 24(2):105-8. PubMed ID: 12187481
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Mouriaux F; Maurage CA; Labalette P; Sablonnière B; Malecaze F; Darbon JM
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2837-43. PubMed ID: 10967035
[TBL] [Abstract][Full Text] [Related]
4. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Enucleation versus enucleation postirradiation groups.
Pe'er J; Gnessin H; Shargal Y; Livni N
Ophthalmology; 1994 Jan; 101(1):56-62. PubMed ID: 7905616
[TBL] [Abstract][Full Text] [Related]
5. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors.
Al-Jamal RT; Kivelä T
Curr Eye Res; 2006 Jan; 31(1):57-67. PubMed ID: 16421020
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
7. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
[TBL] [Abstract][Full Text] [Related]
8. Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma.
Chowers I; Folberg R; Livni N; Pe'er J
Ophthalmology; 2001 Feb; 108(2):367-71. PubMed ID: 11158814
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.
Mooy CM; de Jong PT; Van der Kwast TH; Mulder PG; Jager MJ; Ruiter DJ
Ophthalmology; 1990 Oct; 97(10):1275-80. PubMed ID: 2243677
[TBL] [Abstract][Full Text] [Related]
10. Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study.
Rummelt V; Folberg R; Rummelt C; Gruman LM; Hwang T; Woolson RF; Yi H; Naumann GO
Ophthalmology; 1994 Apr; 101(4):718-27. PubMed ID: 8152768
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.
Brantley MA; Worley L; Harbour JW
Am J Ophthalmol; 2002 Feb; 133(2):242-8. PubMed ID: 11812429
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
13. C-myc oncogene expression in ocular melanomas.
Royds JA; Sharrard RM; Parsons MA; Lawry J; Rees R; Cottam D; Wagner B; Rennie IG
Graefes Arch Clin Exp Ophthalmol; 1992; 230(4):366-71. PubMed ID: 1505770
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of PAX8 Immunohistochemistry in Adult Intraocular Tumor Diagnosis.
Mudhar HS; Milman T; Eagle RC; Sanderson T; Pheasey L; Paine S; Salvi S; Rennie IG; Rundle P; Shields CL; Shields JA
Ophthalmology; 2021 May; 128(5):765-778. PubMed ID: 33002562
[TBL] [Abstract][Full Text] [Related]
15. The value of nucleolar organizer regions in uveal melanoma. The Collaborative Ocular Melanoma Study Group.
Marcus DM; Minkovitz JB; Wardwell SD; Albert DM
Am J Ophthalmol; 1990 Nov; 110(5):527-34. PubMed ID: 1700611
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2 in uveal malignant melanoma.
Jay V; Yi Q; Hunter WS; Zielenska M
Arch Pathol Lab Med; 1996 May; 120(5):497-8. PubMed ID: 8639055
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of the blood-aqueous barrier in human eyes with malignant or benign uveal tumors.
Küchle M; Nguyen NX; Naumann GO
Am J Ophthalmol; 1994 Apr; 117(4):521-8. PubMed ID: 8154537
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
20. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?
Heindl LM; Hofmann TN; Adler W; Knorr HL; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Ophthalmology; 2010 Feb; 117(2):334-42. PubMed ID: 19892405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
